The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life.
The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life.
复制标题
DOI：
10.1097/00006254-200004000-00020
复制
发表时间：
2000-04
期刊：
影响因子：
--
通讯作者：
K. Barnhart;E. Freeman;J. A. Grisso;D. Rader;M. Sammel;S. Kapoor;J. Nestler
中科院分区：
文献类型：
--
作者：
K. Barnhart;E. Freeman;J. A. Grisso;D. Rader;M. Sammel;S. Kapoor;J. Nestler
脱氢表雄酮（DHEA），一种雄激素类固醇激素，表现出与年龄相关的下降。围绝经期妇女只有大约50%的峰值DHEA水平。尽管科学数据有限，但DHEA已被公认为一种膳食补充剂，可减少衰老症状并改善健康状况。这项随机、双盲、安慰剂对照试验研究了每日50毫克口服DHEA补充剂3个月对60名主诉情绪和幸福感改变的围绝经期妇女的影响。DHEA组女性血清内分泌特征的变化显著大于安慰剂组，包括DHEAS增加242% [95%置信区间（CI）+60.1，+423.9]，DHEA增加94.8%[95%置信区间（CI）+60.1，423.9]，DHEA增加94.8%[95%置信区间（CI）+60.1，423.9]。与基线相比，睾酮增加（95% CI +34.2，155.4），皮质醇下降13.2%（95% CI-27.88，0.5）。接受DHEA治疗的女性高密度脂蛋白和Lp（a）较基线水平分别下降了10.1%（95%CI-15.0，-5.1）和18.1%（95%CI-32.2，-3.9），但这些下降与接受安慰剂治疗的女性无显著差异。接受DHEA的妇女在围绝经期症状、情绪、烦躁不安、性欲、认知、记忆或幸福感的严重程度方面没有任何明显大于安慰剂的改善。DHEA补充剂显著影响内分泌特征，可能影响脂质特征，但与安慰剂相比，不会改善围绝经期症状或健康状况。
Dehydroepiandrosterone (DHEA), an androgenic steroid hormone, exhibits an age-related decline. Perimenopausal women have only approximately 50% of peak DHEA levels. Despite limited scientific data, DHEA has gained recognition as a dietary supplement to reduce the symptoms of aging and improve well-being. This randomized, double-blind placebo-controlled trial examined the effects of 50 mg/day of oral DHEA supplementation, for 3 months, on 60 perimenopausal women with complaints of altered mood and well-being. Changes in the serum endocrine profile of women in the DHEA group were significantly greater than the placebo group, including a 242% [95% confidence interval (CI) +60.1, +423.9] increase in DHEAS, a 94.8% (95% CI +34.2, +155.4) increase in testosterone, and a 13.2% (95% CI -27.88, +0.5) decline in cortisol compared to baseline. Women receiving DHEA had a 10.1% (95% CI -15.0, -5.1) decline in high-density lipoprotein and an 18.1% (95% CI -32.2, -3.9) decline in Lp(a) from baseline, but these declines did not significantly differ from women who received placebo. Women receiving DHEA did not have any improvements significantly greater than placebo in the severity of perimenopausal symptoms, mood, dysphoria, libido, cognition, memory, or well-being. DHEA supplementation significantly effects the endocrine profile, may affect the lipid profile, but does not improve perimenopausal symptoms or well-being compared to placebo.